Open an account

Mink Therapeutics

INKT · NASDAQ

$9.86+$0.30 (+3.14%)TodayMarket closed ·
Prev close $9.56

About INKT

The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2021-10-15.

Employees
15
Headquarters
New York City, New York
Listed
Oct 15, 2021
Sector
Health Care
Industry
Biotechnology
Website
minktherapeutics.com

INKT key statistics

Market cap
50.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
19.13K
Volume
8.52K
Open price
$9.40
High today
$9.97
Low today
$9.19
52 Week high
$16.93
52 Week low
$8.48

Mink Therapeutics (INKT) at a glance

As of Oct 20, 2026, Mink Therapeutics (INKT) shares are priced at $9.86, giving the company a market cap of 50.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.19 and $9.97. The current price is 7.3% above the day's low and 1.1% below its high.

Volume so far is 8.52K shares, below the average of 19.13K shares a day.

Over the past year Mink Therapeutics has ranged from $8.48 to $16.93, and now sits 16% of the way up that range.

Mink Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.62 per share against an estimate of -$0.612.

The average analyst price target is $39.78, 303.4% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $39.78
Low
$35.35
Now
$9.86
High
$45.15

INKT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 31.3% on average.

  1. Q3 FY24: reported -$0.50 per share against an estimate of -$0.816
  2. Q4 FY24: reported -$0.62 per share against an estimate of -$0.51
  3. Q1 FY25: reported -$0.70 per share against an estimate of -$0.6222
  4. Q2 FY25: reported -$1.06 per share against an estimate of -$0.5576
  5. Q3 FY25: reported -$0.65 per share against an estimate of -$0.8721
  6. Q4 FY25: reported -$0.555 per share against an estimate of -$0.8364
  7. Q1 FY26: reported -$0.57 per share against an estimate of -$0.7854
  8. Q2 FY26: reported -$0.62 per share against an estimate of -$0.612

INKT news

  • Press releaseBusiness Wire

    Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

  • Press releasePRNewswire

    A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

  • Press releaseBusiness Wire

    Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

  • Press releaseBusiness Wire

    Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

  • Press releaseBusiness Wire

    Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

  • Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseBusiness Wire

    Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Similar companies

Companies in the same industry as Mink Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.